See the story behind Verzenio, a treatment option for HR+, HER2– metastatic breast cancer
Every Day Matters
For women living with HR+, HER2– metastatic breast cancer, every day matters. Learn about an everyday CDK4 & 6 inhibitor for a relentless disease.
The Relentless Story
Every story starts with an inspiration. The Verzenio story started years ago when it was first envisioned in a laboratory, inspired by women with metastatic breast cancer, and a mission to help them. They are at the heart of everything we do.
See the story behind the first everyday, twice-a-day CDK4 & 6 inhibitor for HR+, HER2– metastatic breast cancer, which was inspired by the relentless women living with this disease.